Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Cuneo – page 5

81 clinical trials in Cuneo, Italy. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Cuneo at a glance
81
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

81 trials in Cuneo

Open in trial search

Porphyria non-acute

Not recruiting

Study on the Safety and Tolerability of Oral Dersimelagon for Patients with Erythropoietic Protoporphyria or X-Linked Protoporphyria

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dersimelagon Phosphate
  • Sponsor:Tanabe Pharma America Inc.

Acute myeloid leukaemia

Not recruiting

Study of venetoclax with fludarabine, cytarabine and idarubicin combination therapy in newly diagnosed patients with intermediate or high-risk Acute Myeloid Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Chronic lymphocytic leukaemia

Not recruiting

Study of Ibrutinib for Patients with Chronic Lymphocytic Leukemia and TP53 Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Ospedale San Raffaele S.r.l.

Chronic lymphocytic leukaemia+1

Not recruiting

Study on Ibrutinib and Venetoclax for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Ospedale San Raffaele S.r.l.

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Melphalan, Prednisone, Lenalidomide, and Daratumumab for Multiple Myeloma in Patients Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Bortezomib
  • Sponsor:Universita' Degli Studi Di Torino

Mantle cell lymphoma recurrent+1

Not recruiting

Study on Loncastuximab Tesirine for Patients with Relapsed or Refractory Mantle Cell Lymphoma After Immunochemotherapy with Rituximab, Bendamustine, and Cytarabine

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Loncastuximab Tesirine
  • Sponsor:Fondazione Italiana Linfomi Ets

Squamous cell carcinoma of head and neck

Not recruiting

Study of petosemtamab compared to standard therapy in previously treated patients with metastatic or recurrent head and neck cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Genmab A/S

Mantle cell lymphoma

Not recruiting

Study on Rituximab, Bendamustine, Cytarabine, and Venetoclax for High-Risk Elderly Patients with Mantle Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione Italiana Linfomi Ets

Plasma cell myeloma

Not recruiting

Study Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Colorectal cancer metastatic

Not recruiting

Study Comparing Panitumumab and Regorafenib Sequence for Patients with Metastatic Colorectal Cancer Resistant to Previous Treatments

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:Fondazione GONO G.I.

Colorectal cancer metastatic+1

Not recruiting

Study on the Safety and Effectiveness of Trifluridine/Tipiracil, Capecitabine, and Bevacizumab for Patients with Metastatic Colorectal Cancer Unfit for Intensive Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione GONO G.I.

Acute lymphocytic leukaemia

Not recruiting

Study on Ponatinib and Chemotherapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Cuneo

What the registry says about research in the country

01 Hematologic Oncology

Groundbreaking trials focusing on Acute Myeloid Leukemia (AML) and various lymphomas, testing innovative combination therapies and transplantation approaches.

  • Leukemia treatments
  • Stem cell transplantation
  • Novel drug combinations

Studies evaluating targeted therapies for Multiple Myeloma and Chronic Lymphocytic Leukemia.

02 Solid Tumors

Research examining innovative treatments for breast cancer, including trials for triple-negative and hormone-responsive subtypes.

  • Immunotherapy combinations
  • Targeted therapies
  • Maintenance treatments

Advanced studies in ovarian cancer and lung cancer, exploring novel therapeutic approaches.

03 Emerging Therapeutics

Investigating immunotherapy approaches across multiple cancer types, with focus on combination strategies.

  • Antibody therapies
  • Targeted molecules
  • Maintenance protocols

Evaluation of novel drug combinations and treatment sequences for optimal patient outcomes.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.